NCT07852377Not yet recruiting
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
Immunomonitoring and Identification of Predictive Biomarkers of Response, Toxicity and Risk of Relapse After CAR-T Cells in B-cell Lymphomas and Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints. Up to 45 adults with relapsed or refractory B-cell lymphoma or multiple myeloma who are scheduled to receive standard-of-care anti-CD19 or anti-BCMA CAR-T cells will be enrolled. The study will characterize CAR-positive and endogenous CAR-negative T-cell populations and T-cell receptor clonality at apheresis, in the CAR-T product, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These findings will be related to treatment response, toxicities and relapse during 12 months of follow-up. The study hypothesis is that dynamic immunological and molecular characteristics measured along the CAR-T pathway are associated with early response, toxicity and relapse risk.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- 18 Sept 2026
- Primary completion date
- 2 Nov 2027
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Multiple myeloma
- NCT number
- NCT07852377
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 18 Sept 2026 to the primary completion date, 2 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous exposure to anti-BCMA bispecific antibodies or need for anti-BCMA bispecific antibodies as bridging therapy before anti-BCMA CAR-T cell administration.
Other
- Pregnant or breastfeeding.
- Absence of informed consent.
- Primary central nervous system lymphoma or primary vitreoretinal lymphoma.
- Body weight below 30 kg.
- Protected adult or person deprived of liberty under guardianship or curatorship.
- Inability to understand the study or comply with study constraints for language, psychological, geographical or other reasons.
Who the study is looking for
- Age 18 years or older.
- Relapsed or refractory B-cell lymphoma or multiple myeloma.
- Indication for anti-CD19 or anti-BCMA CAR-T cell treatment.
- Signed informed consent.
- Affiliation to or beneficiary status under a health insurance scheme.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.